" class="no-js "lang="en-US"> Envirotainer and Swiss WorldCargo Complete the First Commercial Shipment Using the New Releye® RAP - Medtech Alert
Wednesday, May 15, 2024

Envirotainer and Swiss WorldCargo Complete the First Commercial Shipment Using the New Releye® RAP

Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that the first commercial shipment using the new Releye® RAP container has been completed. The consignment was handled by Swiss WorldCargo, one of the leading carriers of intensive care pharmaceuticals.

The shipment started in Basel, Switzerland, landing at JFK in the US and comprised of three Releye® RAP units and two RAP e2 units. The shipper was a global acting Swiss pharmaceutical company, and the transportation was successful and went according to plan.

Thanks to the integrated live monitoring, the shipment was checked in every detail through the whole journey. Furthermore, with Envirotainer’s new Control Tower service, a global team of operators stood ready to respond within minutes to any critical event, if one should have occurred. The Envirotainer Control Tower service is included in all Releye® leases.

And, since the Releye® RAP is based on exactly the same platform and technology as the Releye® RLP together with the comprehensive data made available, the qualification for the pharmaceutical company customer required marginal effort and went exceptionally fast. 

For more information, please visit www.envirotainer.com/releye

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
More On